Call for Papers
In the last years the immuno-oncology has represented a break point in cancer treatment and many new therapies have been recently developed and utilized in the clinical practice. The majority of these novel therapeutic approaches have been designed to potentiate the anti-tumor immune responses of T lymphocytes by acting on inhibitory or activating pathways. Although these therapies showed remarkable results, the efficacy of these treatments appears to be limited only to tumors characterized by high pre-existing T cell infiltration, the so-called “hot” tumors, whereas the T-cell excluded “cold” cancers are poorly responsive.
However, it should be highlighted that a large proportion of tumor-associated immune cells belongs to the innate arm of the immune system, including macrophages, dendritic (DCs), myeloid cells, natural killer (NK) cells, γδ T cells and innate lymphoid cells (ILCs). All these immune populations have been demonstrated to participate to the “innate sensing” of tumors, representing a promising target for the treatment of “cold” tumors. In particular, macrophages have emerged as an attractive therapeutic target for cancer immunotherapies as they are frequently found infiltrating the tumor bed and are involved in restraining the cytotoxic activity of T lymphocytes and, in general, the anti-tumor immune responses.
The present Special Issue aims to collect original research articles and reviews about the role of innate cells in the tumor microenvironment and how these cells can be manipulated to boost their anti-tumor activity. Research areas may include but are not limited to: detection of tumor cells by the innate immune system, cross-talk between adaptive and innate immune cells, mechanisms of immunesupression exerted by innate immune system, novel therapeutic strategies to promote tumor cell killing by innate immune cells.
We are pleased to invite you to contribute in this field that is emerging extremely important in fighting cancer, highlighting strategies that could open up new therapeutic possibilities.
We look forward to receiving your contributions.
Dr. Lucia Sfondrini
Dr. Valentino Mario Le Noci
Dr. Michele Sommariva
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
antigen presenting cells
innate lymphoid cells
This special issue is now open for submission.
Credits and Sources
| Cancers (ISSN 2072-6694). 2022 : MDPI - CANCERS - Special Issue: Innate Immunity in Cancer Therapy